{
    "clinical_study": {
        "@rank": "60509", 
        "acronym": "KRG", 
        "arm_group": [
            {
                "arm_group_label": "Korean Red Ginseng", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive oral Korean Red Ginseng twice daily for 16 weeks. Treatment repeats every 4 weeks for 4 courses.\nIntervention: Dietary Supplement: Korean Red Ginseng"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients receive oral placebo twice daily for 16 weeks. Treatment repeats every 4 weeks for 4 courses.\nIntervention: Other: Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Korean Red Ginseng may improve fatigue in healthy subject. It is not yet known whether\n      Korean Red Ginseng is effective compared with a placebo in chemotherapy.\n\n      The purpose of this study is to determine whether Korean Red Ginseng is effective in the\n      treatment of the fatigue from colorectal cancer with chemotherapy.(modified FOLFOX-6)"
        }, 
        "brief_title": "Korean Red Ginseng in Treating Patients With Fatigue Caused by Chemotherapy for Colorectal Cancer", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Colorectal Neoplasms", 
                "Fatigue"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  20 years and older\n\n          -  Person who agreed to participate in this study and signed voluntarily on the written\n             informed consent form\n\n          -  Person who is confirmed as colorectal cancer through histological and image diagnosis\n             and scheduled for adjuvant or palliative therapy with mFOLFOX-6 regimen\n\n          -  Fertile patients with negative pregnancy test confirmed and who has agreed to use\n             effective contraception\n\n          -  Person who is able to fully communicate with the physician about his/her fatigue\n             status and is able to completely fill out the questionnaires\n\n          -  Life expectancy more than 6 months\n\n          -  Performance status of ECOG grade 0~1\n\n          -  Hb \u2265 9g/dL\n\n          -  Person with moderate liver function (AST, ALT \u2264 2.5 \u00d7 ULN)\n\n          -  Person with moderate renal function (Cr \u2264 1.5 \u00d7 ULN)\n\n        Exclusion Criteria:\n\n          -  Pregnant or nursing women\n\n          -  Primary brain cancer, brain metastases or other CNS malignancy, including CNS\n             lymphoma\n\n          -  No controlled pain despite the use if analgesics.\n\n          -  Person showing hypothyroidism despite the hormone treatment\n\n          -  Person with insomnia despite an appropriate treatment\n\n          -  No controlled hypertension (DBP \u3009100mmHg or SBP \u3009160mmHg)\n\n          -  Person who has experience of hypersensitivity to the trial drug (ginseng)  components\n\n          -  Person with autoimmune disorders (Multiple sclerosis, Lupus, rheumarthritis etc.)\n\n          -  Person who is alcoholic dependent or has psychiatric disorder\n\n          -  Person who has cognitive or psychiatric problems\n\n          -  Person who has an experience of chemotherapy agents use 6 months before a screening\n             visit\n\n          -  Person who had a surgery 2 weeks before a screening visit\n\n          -  Person who had taken herbal medicinal product (including Chinese medicine) 4 weeks\n             before the screening visit\n\n          -  Person who has medical status that is judged to affect the result or who is judged as\n             inappropriate for the study by the physician"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "438", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02039635", 
            "org_study_id": "KGC-S-02"
        }, 
        "intervention": [
            {
                "arm_group_label": "Korean Red Ginseng", 
                "description": "Given Orally", 
                "intervention_name": "Korean Red Ginseng", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Given Orally", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "cancer", 
            "cancer related fatigue", 
            "Korean red ginseng", 
            "chemotherapy"
        ], 
        "lastchanged_date": "April 3, 2014", 
        "location": {
            "contact": {
                "email": "bchan@kgc.or.kr", 
                "last_name": "byungcheol han, MS"
            }, 
            "contact_backup": {
                "email": "20130021@kgc.or.kr", 
                "last_name": "jungyoon woo, MS"
            }, 
            "facility": {
                "address": {
                    "city": "Shinseongdong", 
                    "country": "Korea, Republic of", 
                    "state": "Daejeon", 
                    "zip": "305-805"
                }, 
                "name": "Korea Ginseng Corporation"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Study of Korean Red Ginseng for Evaluation of Improvement of Cancer-related Fatigue in Patients With Colorectal Cancer With Chemotherapy: A Randomized, Double-blind, Placebo-Controlled, Parallel, Multicenter Trial", 
        "other_outcome": [
            {
                "measure": "Tumor response after 8 and 16 weeks of trial drug intake", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 8 and 16 weeks"
            }, 
            {
                "measure": "Progressive-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "up to 16 weeks"
            }, 
            {
                "measure": "Change in blood cytokine(IL-2, IL-8, IL-10) level after 16 weeks of trial drug intake", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 16 weeks"
            }
        ], 
        "overall_contact": {
            "email": "yhk0215@korea.ac.kr", 
            "last_name": "Yeul Hong Kim, MD, Ph D"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Area Under Curve (AUC) of Brief Fatigue Index (BFI) on the intake trial drugs up to 16 weeks", 
            "safety_issue": "No", 
            "time_frame": "From Baseline up to 16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02039635"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area Under Curve (AUC) of Brief Fatigue Index (BFI) on the intake of trial drugs up to 8 weeks", 
                "safety_issue": "No", 
                "time_frame": "From Baseline up to 8 weeks"
            }, 
            {
                "measure": "Change in Functional Assessment of Chronic Illness Therapy-Fatigue Trial Outcome Index (FACIT-F TOI) after 8 and 16 weeks of trial drug intake", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 8 and 16 weeks"
            }, 
            {
                "measure": "Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) total score after 8 and 16 weeks of trial drug in take", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 8 and 16 weeks"
            }, 
            {
                "measure": "The percentage of subjects whom the Functional Assessment of Cancer Therapy-General  (FACT-G) score decreased more than 20 scores after 8 and 16 weeks of trial drug intake", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 8 and 16 weeks"
            }, 
            {
                "measure": "Change in blood cytokine (IL-1, IL-6, TNF-alpha) level after 16 weeks of trial drug intake", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 16 weeks"
            }, 
            {
                "measure": "Change in blood cortisol level after 16 weeks of trial drug intake", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 16 weeks"
            }, 
            {
                "measure": "Perceived Stress Scale (PSS) change after 16 weeks of trial drug intake", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 16 weeks"
            }, 
            {
                "description": "Voluntary reports of adverse events and collected reports of adverse events (agitation, anxiety, headache, insomnia, vomiting)\nLaboratory and physical test\nECOG performance\nECG", 
                "measure": "adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, 8 and 16 weeks"
            }
        ], 
        "source": "Korea Ginseng Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Korea Ginseng Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}